Managing Toxicities in Advanced Ovarian Cancer

preview_player
Показать описание
Insights into the management of treatment-related toxicities for patients with advanced ovarian cancer who are receiving carboplatin, paclitaxel, and bevacizumab.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Managing Toxicities in 0:02:36

Managing Toxicities in Advanced Ovarian Cancer

Managing Toxicities in 0:04:38

Managing Toxicities in Ovarian Cancer Treatments

Toxicities Associated With 0:02:15

Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer

Dr. Chase on 0:02:41

Dr. Chase on Toxicities of Treatments for Ovarian Cancer

Experience Managing Newly 0:02:56

Experience Managing Newly Diagnosed Advanced Ovarian Cancer

Management of Niraparib 0:01:54

Management of Niraparib Dosing in Ovarian Cancer

Advances in the 0:29:21

Advances in the Management of Cervical and Endometrial carcinoma

Toxicities Associated with 0:02:31

Toxicities Associated with PARP Inhibitors in Ovarian Cancer

Practice-Changing Updates in 1:04:52

Practice-Changing Updates in Ovarian Cancer: Implications for Pathways Construction

Dr. Coleman Discusses 0:01:36

Dr. Coleman Discusses the Toxicities Associated With Rucaparib in Patients With Ovarian Cancer

Management of PARP 0:05:38

Management of PARP Inhibitor AEs in Ovarian Cancer

SOLO3 Highlights Toxicities 0:01:11

SOLO3 Highlights Toxicities With Olaparib in Ovarian Cancer

PARP Inhibitor Toxicity 0:07:14

PARP Inhibitor Toxicity Management

Advances in the 0:24:20

Advances in the Management of Advanced and Relapsed Ovarian Cancer

Expanding the Treatment 1:01:16

Expanding the Treatment Landscape for Recurrent Low-Grade Serous Ovarian Cancer

Targeted Therapy in 0:03:48

Targeted Therapy in Newly Diagnosed Advanced Ovarian Cancer

Advancements in Ovarian 1:19:12

Advancements in Ovarian Cancer Screening and Treatment

Newly Diagnosed Advanced 0:04:31

Newly Diagnosed Advanced Ovarian Cancer: Case Reactions

Muscle density as 0:05:04

Muscle density as a predictive marker for toxicities during ovarian cancer treatment

Management of Ovarian 0:22:41

Management of Ovarian Cancer: Diagnosis to Survivorship and Ovarcoming

PARP Inhibitors in 0:08:03

PARP Inhibitors in Ovarian Cancer: Safety Profile

Olaparib and bevacizumab: 0:06:01

Olaparib and bevacizumab: On the horizon for treating ovarian cancer

Dr Timothy Yap: 0:01:17

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery

Novel Therapies for 0:04:56

Novel Therapies for Newly Diagnosed Advanced Ovarian Cancer

visit shbcf.ru